Table 3 Genotype at the second locus of codon 119 by resistance phenotype, for (a) P2 (malathion and fenitrothion), (b) P3 (fenitrothion) (c) by intensity of resistance to fenitrothion in P3 and (d) bendiocarb, P3
Phenotype | Heterozygote (G/C) | Homozygote (C/C) | Total |
|---|---|---|---|
(a) | Â | Â | Â |
Susceptible | 99(73.9%) | 35(26.1%) | 134(100%) |
Resistant | 27(50.0%) | 27(50.0%) | 54(100%) |
(b) | Â | Â | Â |
Susceptible | 34(89.5%) | 4(10.5%) | 38(100%) |
Resistant | 31(59.6%) | 21(40.4%) | 52(100%) |
(c) | Â | Â | Â |
1x diagnostic dose | Â | Â | Â |
Susceptible | 3(75.0%) | 1(25.0%) | 4(100%) |
Resistant | 12(63.2%) | 7(36.8%) | 19(100%) |
2x diagnostic dose | Â | Â | Â |
Susceptible | 6(100%) | 0(0%) | 6(100%) |
Resistant | 10(62.5%) | 6(37.5%) | 16(100%) |
5x diagnostic dose | Â | Â | Â |
Susceptible | 11(84.6%) | 2(15.4%) | 13(100%) |
Resistant | 6(60.0%) | 4(40.0%) | 10(100%) |
10x diagnostic dose | Â | Â | Â |
Susceptible | 14(93.3%) | 1(6.7%) | 15(100%) |
Resistant | 3(42.9%) | 4(57.1%) | 7(100%) |
(d) | Â | Â | Â |
Susceptible | 30(85.7%) | 5(14.3%) | 35(100%) |
Resistant | 41(63.1%) | 24(36.9%) | 65(100%) |